Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients

M G Bousser; M Amarenco; A Chamorro; M Fisher; I Ford; K Fox; Michael Hennerici; H P Mattle; Peter Malcolm W Rothwell; Christopher Bladin

doi:10.1159/000212671

Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients

M G Bousser, M Amarenco, A Chamorro, M Fisher, I Ford, K Fox, Michael Hennerici, H P Mattle, Peter Malcolm W Rothwell, Christopher Bladin

Eastern Health Clinical School

Research output: Contribution to journal › Article › Research › peer-review

69 Citations (Scopus)

Original language	English
Pages (from-to)	509 - 518
Number of pages	10
Journal	Cerebrovascular Diseases
Volume	27
Issue number	5
DOIs	https://doi.org/10.1159/000212671
Publication status	Published - 2009

Access to Document

10.1159/000212671

Cite this

Bousser, M. G., Amarenco, M., Chamorro, A., Fisher, M., Ford, I., Fox, K., Hennerici, M., Mattle, H. P., Rothwell, P. M. W., & Bladin, C. (2009). Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients. Cerebrovascular Diseases, 27(5), 509 - 518. https://doi.org/10.1159/000212671

@article{a8a759401e70481584022247979c894d,

title = "Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients",

author = "Bousser, \{M G\} and M Amarenco and A Chamorro and M Fisher and I Ford and K Fox and Michael Hennerici and Mattle, \{H P\} and Rothwell, \{Peter Malcolm W\} and Christopher Bladin",

year = "2009",

doi = "10.1159/000212671",

language = "English",

volume = "27",

pages = "509 -- 518",

journal = "Cerebrovascular Diseases",

issn = "1015-9770",

publisher = "S Karger AG",

number = "5",

}

Bousser, MG, Amarenco, M, Chamorro, A, Fisher, M, Ford, I, Fox, K, Hennerici, M, Mattle, HP, Rothwell, PMW & Bladin, C 2009, 'Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients', Cerebrovascular Diseases, vol. 27, no. 5, pp. 509 - 518. https://doi.org/10.1159/000212671

Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients. / Bousser, M G; Amarenco, M; Chamorro, A et al.
In: Cerebrovascular Diseases, Vol. 27, No. 5, 2009, p. 509 - 518.

Research output: Contribution to journal › Article › Research › peer-review

TY - JOUR

T1 - Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients

AU - Bousser, M G

AU - Amarenco, M

AU - Chamorro, A

AU - Fisher, M

AU - Ford, I

AU - Fox, K

AU - Hennerici, Michael

AU - Mattle, H P

AU - Rothwell, Peter Malcolm W

AU - Bladin, Christopher

PY - 2009

Y1 - 2009

UR - http://www.ncbi.nlm.nih.gov/pubmed/19372653

UR - https://www.scopus.com/pages/publications/64549164466

U2 - 10.1159/000212671

DO - 10.1159/000212671

M3 - Article

SN - 1015-9770

VL - 27

SP - 509

EP - 518

JO - Cerebrovascular Diseases

JF - Cerebrovascular Diseases

IS - 5

ER -

Bousser MG, Amarenco M, Chamorro A, Fisher M, Ford I, Fox K et al. Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients. Cerebrovascular Diseases. 2009;27(5):509 - 518. doi: 10.1159/000212671

Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients

Access to Document

Other files and links

Cite this